171 related articles for article (PubMed ID: 36877839)
1.
Guardia T; Zhang Y; Thompson KN; Lee SJ; Martin SS; Konstantopoulos K; Kontrogianni-Konstantopoulos A
Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2215553120. PubMed ID: 36877839
[TBL] [Abstract][Full Text] [Related]
2. Obscurin: A multitasking giant in the fight against cancer.
Guardia T; Eason M; Kontrogianni-Konstantopoulos A
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188567. PubMed ID: 34015411
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA ZEB2-AS1 promotes the proliferation, metastasis and epithelial mesenchymal transition in triple-negative breast cancer by epigenetically activating ZEB2.
Zhang G; Li H; Sun R; Li P; Yang Z; Liu Y; Wang Z; Yang Y; Yin C
J Cell Mol Med; 2019 May; 23(5):3271-3279. PubMed ID: 30825262
[TBL] [Abstract][Full Text] [Related]
4. Giant obscurin regulates migration and metastasis via RhoA-dependent cytoskeletal remodeling in pancreatic cancer.
Tuntithavornwat S; Shea DJ; Wong BS; Guardia T; Lee SJ; Yankaskas CL; Zheng L; Kontrogianni-Konstantopoulos A; Konstantopoulos K
Cancer Lett; 2022 Feb; 526():155-167. PubMed ID: 34826548
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA MIDEAS-AS1 inhibits growth and metastasis of triple-negative breast cancer via transcriptionally activating NCALD.
Luo D; Liang Y; Wang Y; Ye F; Jin Y; Li Y; Han D; Wang Z; Chen B; Zhao W; Wang L; Chen X; Jiang L; Yang Q
Breast Cancer Res; 2023 Sep; 25(1):109. PubMed ID: 37770991
[TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNA ST8SIA6-AS1 promotes cell proliferation and metastasis in triple-negative breast cancer by targeting miR-145-5p/CDCA3 to inactivate the p53/p21 signaling pathway.
Qiao Y; Wang B; Yan Y; Niu L
Environ Toxicol; 2022 Oct; 37(10):2398-2411. PubMed ID: 35730485
[TBL] [Abstract][Full Text] [Related]
7. LncRNA FAM83H-AS1 promotes triple-negative breast cancer progression by regulating the miR-136-5p/metadherin axis.
Han C; Fu Y; Zeng N; Yin J; Li Q
Aging (Albany NY); 2020 Feb; 12(4):3594-3616. PubMed ID: 32074085
[TBL] [Abstract][Full Text] [Related]
8. A natural antisense lncRNA controls breast cancer progression by promoting tumor suppressor gene mRNA stability.
Jadaliha M; Gholamalamdari O; Tang W; Zhang Y; Petracovici A; Hao Q; Tariq A; Kim TG; Holton SE; Singh DK; Li XL; Freier SM; Ambs S; Bhargava R; Lal A; Prasanth SG; Ma J; Prasanth KV
PLoS Genet; 2018 Nov; 14(11):e1007802. PubMed ID: 30496290
[TBL] [Abstract][Full Text] [Related]
9. Proliferation-associated long noncoding RNA, TMPO-AS1, is a potential therapeutic target for triple-negative breast cancer.
Mitobe Y; Ikeda K; Sato W; Kodama Y; Naito M; Gotoh N; Miyata K; Kataoka K; Sasaki H; Horie-Inoue K; Inoue S
Cancer Sci; 2020 Jul; 111(7):2440-2450. PubMed ID: 32437068
[TBL] [Abstract][Full Text] [Related]
10. TGFB2-AS1 inhibits triple-negative breast cancer progression via interaction with SMARCA4 and regulating its targets
Zhou C; Wang D; Li J; Wang Q; Wo L; Zhang X; Hu Z; Wang Z; Zhan M; He M; Hu G; Chen X; Shen K; Chen GQ; Zhao Q
Proc Natl Acad Sci U S A; 2022 Sep; 119(39):e2117988119. PubMed ID: 36126099
[TBL] [Abstract][Full Text] [Related]
11. Loss of giant obscurins from breast epithelium promotes epithelial-to-mesenchymal transition, tumorigenicity and metastasis.
Shriver M; Stroka KM; Vitolo MI; Martin S; Huso DL; Konstantopoulos K; Kontrogianni-Konstantopoulos A
Oncogene; 2015 Aug; 34(32):4248-59. PubMed ID: 25381817
[TBL] [Abstract][Full Text] [Related]
12. lncRNA AFAP1-AS1 promotes triple negative breast cancer cell proliferation and invasion via targeting miR-145 to regulate MTH1 expression.
Zhang X; Zhou Y; Mao F; Lin Y; Shen S; Sun Q
Sci Rep; 2020 May; 10(1):7662. PubMed ID: 32376943
[TBL] [Abstract][Full Text] [Related]
13. Down-regulated long non-coding RNA RNAZFHX4-AS1 suppresses invasion and migration of breast cancer cells via FAT4-dependent Hippo signaling pathway.
Li SY; Wang H; Mai HF; Li GF; Chen SJ; Li GS; Liang BC
Cancer Gene Ther; 2019 Nov; 26(11-12):374-387. PubMed ID: 30546116
[TBL] [Abstract][Full Text] [Related]
14. LncRNA WEE2-AS1 promotes proliferation and inhibits apoptosis in triple negative breast cancer cells via regulating miR-32-5p/TOB1 axis.
Wang R; Huang Z; Qian C; Wang M; Zheng Y; Jiang R; Yu C
Biochem Biophys Res Commun; 2020 Jun; 526(4):1005-1012. PubMed ID: 32307083
[TBL] [Abstract][Full Text] [Related]
15. The natural antisense transcript HAS2-AS1 regulates breast cancer cells aggressiveness independently from hyaluronan metabolism.
Parnigoni A; Caon I; Teo WX; Hua SH; Moretto P; Bartolini B; Viola M; Karousou E; Yip GW; Götte M; Heldin P; Passi A; Vigetti D
Matrix Biol; 2022 May; 109():140-161. PubMed ID: 35395387
[TBL] [Abstract][Full Text] [Related]
16. EPHA2 antisense RNA modulates EPHA2 mRNA levels in basal-like/triple-negative breast cancer cells.
Okuyama T; Sakamoto R; Kumagai K; Nishizawa M; Kimura T; Sugie T; Kimura T
Biochimie; 2020 Dec; 179():169-180. PubMed ID: 33022313
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA BRE-AS1 inhibits the proliferation, migration, and invasion of cancer cells in triple-negative breast cancer and predicts patients' survival by downregulating miR-21.
Gao J; Wang S; Zhang Z; Li J
BMC Cancer; 2021 Jun; 21(1):745. PubMed ID: 34182945
[TBL] [Abstract][Full Text] [Related]
18. LncRNA SLCO4A1-AS1 suppresses lung cancer progression by sequestering the TOX4-NTSR1 signaling axis.
Chen YL; Liu YN; Lin YT; Tsai MF; Wu SG; Chang TH; Hsu CL; Wu HD; Shih JY
J Biomed Sci; 2023 Sep; 30(1):80. PubMed ID: 37726723
[TBL] [Abstract][Full Text] [Related]
19. SP1-Induced Upregulation of LncRNA AFAP1-AS1 Promotes Tumor Progression in Triple-Negative Breast Cancer by Regulating mTOR Pathway.
Li F; Xian D; Huang J; Nie L; Xie T; Sun Q; Zhang X; Zhou Y
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686205
[TBL] [Abstract][Full Text] [Related]
20. The role of AFAP1-AS1 in mitotic catastrophe and metastasis of triple-negative breast cancer cells by activating the PLK1 signaling pathway.
Cen S; Peng X; Deng J; Jin H; Deng Z; Lin X; Zhu DI; Jin M; Zhu Y; Zhang P; Luo Y; Huang H
Oncol Res; 2023; 31(3):375-388. PubMed ID: 37305386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
